OSR Health, Inc. (OSRH)
| Market Cap | 7.72M -49.0% |
| Revenue (ttm) | 1.81M -50.2% |
| Net Income | -10.73M |
| EPS | -0.38 |
| Shares Out | 35.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 186,740 |
| Open | 0.1900 |
| Previous Close | 0.1900 |
| Day's Range | 0.1900 - 0.2200 |
| 52-Week Range | 0.0750 - 0.9078 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About OSR Health
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-... [Read more]
Financial Performance
In 2025, OSR Health's revenue was $2.91 million, a decrease of -17.69% compared to the previous year's $3.53 million. Losses were -$18.01 million, 74.4% more than in 2024.
Financial StatementsNews
Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report o...
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, In...
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Det...
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Heal...
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today r...
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning...
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today ...
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication...
OSR Health, A Message From the CEO
BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders. To Every OSR Health Shareholder: OSR H...
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating ...
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones BELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:O...
OSR Holdings changes corporate name to OSR Health
OSR Holdings (OSRH) has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly reflects the Company’s mission. The change became effective on June 11,…
OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do
BELLEVUE, WA / ACCESS Newswire / June 22, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more dire...
CEO Statement to Shareholders
BELLEVUE, WA / ACCESS Newswire / June 3, 2026 / Dear Fellow Shareholders, As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are app...
OSR Holdings acquires full VXM01 intellectual property portfolio for $30M
OSR Holdings (OSRH) announced it has entered into a definitive Asset Purchase Agreement with VAXIMM AG to acquire the full global intellectual property portfolio and related assets for an aggregate…
OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction
Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare h...
OSR Holdings CEO says company not pursuing reverse stock split
OSR Holdings (OSRH) CEO Kuk Hhyoun Hwang said that the company’s Preliminary Proxy Statement on Schedule PRE 14A did not include a proposal authorizing a reverse stock split. “Management has…
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target o...
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare hold...
OSR Holdings enters $815M global license agreement for VXM01 with BCM Europe
OSR Holdings (OSRH) entered into a definitive global exclusive license agreement with BCM Europe for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral imm...
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings, ...
OSR Holdings eliminates $2.02M warrant overhang
OSR Holdings (OSRH) announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund, centered on the retirement of approximately $2.02M of warrant overhang. As...
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with Whit...
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026
BELLEVUE, WA / ACCESS Newswire / March 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today...
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
NEW YORK CITY, NY / ACCESS Newswire / March 27, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price ...